The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.

Background And Aims: Non-alcoholic steatohepatitis has become a leading cause of cirrhosis. The prognostic value of (HVPG)-guided NSBB prophylaxis remains to be investigated in the setting of NASH cirrhosis.

Methods: Patients with NASH cirrhosis and varices undergoing HVPG-guided NSBB therapy were included.